Contract research organisation (CRO) PPD has appointed Daniel Burch, Puneet Mohan and Alan Solinger to fill three new therapeutic area head positions.
The move expands the company’s expertise in CNS, cardiovascular/metabolism and rheumatology/immunology and swells its global product department team.
Daniel Burch (pictured top right) joins PPD from CeNeRx BioPharma, where he was executive VP of R&D and chief medical officer. Prior to joining CeNeRx, Burch was at GlaxoSmithKline (GSK), where he most recently served as senior VP and head of GSK’s neurosciences medicine development centre.
He has 20 years of experience in general management, global drug development, global medical affairs and business development.
Puneet Mohan (left) comes to PPD from Bristol-Myers Squibb, where he most recently served as executive director of global clinical development and global clinical leader for Eliquis (apixaban).
He held this role for eight of his 29-year medical career and prior to serving at BMS, Mohan was with Bayer.
Alan Solinger’s (bottom right) medical career covers 30 years and he joins PPD from Californian biotech company Xoma, where he served as vice president of clinical immunology.
PPD’s global product development team of six therapeutic area heads is managed by its global head of medical affairs Rob Dow.
“These experts have held senior leadership roles in top biopharma companies, and their expertise will bring added strategic value to our clients. I am pleased to welcome them to our team,” he said.
Burch, Mohan and Solinger join PPD’s existing therapeutic area heads of Carol Olson (infectious diseases), Dirk Reitsma (oncology) and Peter Summerfield (respiratory).